Agriculture · Founded 1982 · www.shreeganeshbiotech.bar · BSE 539470 · · ISIN INE051N01026
No Notes Added Yet
Business
Shree Ganesh Bio-Tech (India) Ltd. is an Indian agriculture company primarily engaged in the business of developing, producing, processing, and marketing various types of hybrid seeds. The company's product portfolio typically includes seeds for major field crops like cotton, maize (corn), paddy (rice), wheat, and a range of vegetable seeds. Its core business model revolves around selling these high-yielding hybrid seeds directly to farmers through a network of distributors and dealers, generating revenue from the sales of these agricultural inputs.
Revenue Mix
The company's primary and most significant revenue segment is the Seeds business. While specific breakdowns by crop type (e.g., percentage contribution from cotton vs. maize) are generally not publicly disclosed for companies of this size, the vast majority of its income is derived from the sale of hybrid crop seeds.
Industry
The Indian agriculture industry, particularly the seed sector, is vast, fragmented, and competitive. It includes numerous national, regional, and multinational players (e.g., Kaveri Seeds, Nuziveedu Seeds, Bayer CropScience). Shree Ganesh Bio-Tech operates within this landscape, likely positioning itself as a regional or a smaller national player with a focus on specific crop varieties or geographical pockets. Its positioning relies on the efficacy of its hybrid seeds and its distribution reach within its operational areas, competing on factors like yield, pest resistance, and pricing.
MOAT
Shree Ganesh Bio-Tech's potential competitive advantages are likely localized and include:
Proprietary Germplasm/Hybrids: Development and ownership of specific, high-performing hybrid seed varieties suited for local agro-climatic conditions.
Regional Distribution Network: Established relationships with farmers and a distribution network in its key operating regions.
Brand Recognition: Limited brand recognition among specific farmer communities for certain successful crop varieties.
R&D Capabilities: Investment in localized research and development to introduce new and improved seed varieties.
These advantages tend to be less durable than those of larger, globally diversified players with massive R&D budgets and patent portfolios.
Growth Drivers
Key factors that can drive growth for Shree Ganesh Bio-Tech over the next 3-5 years include:
Increasing Food Demand: Growing population and rising income levels in India drive demand for food and, consequently, agricultural output.
Shift to Hybrid Seeds: Continued adoption of high-yielding hybrid seeds by farmers seeking better productivity and profitability.
Government Support: Favorable government policies for agriculture, including subsidies for inputs, irrigation, and crop insurance, can stimulate demand.
Expansion into New Crops/Geographies: Successful introduction of new hybrid varieties or expansion into untapped regions within India.
Technological Advancements: Adoption of new breeding technologies to develop superior seeds faster.
Risks
The company faces several key business risks:
Monsoon Dependency: Agricultural output and farmer income are highly dependent on adequate and timely monsoons, leading to demand volatility.
Pest & Disease Outbreaks: Outbreaks can severely impact crop yields and farmer profitability, reducing demand for seeds.
Commodity Price Volatility: Fluctuations in agricultural commodity prices directly affect farmer's purchasing power and willingness to invest in quality seeds.
Intense Competition: The presence of numerous domestic and international players creates pricing pressure and market share challenges.
Regulatory Risks: Changes in government policies regarding seed varieties (e.g., genetically modified crops), pricing, or imports can significantly impact operations.
Counterfeit Seeds: The presence of counterfeit seeds in the market can erode farmer trust and company reputation.
Working Capital Management: The seasonal nature of the seed business requires careful management of inventory and receivables.
Management & Ownership
Shree Ganesh Bio-Tech (India) Ltd. is typically promoted and controlled by the founding family. Promoter ownership generally constitutes a significant portion of the company's equity, indicating direct alignment between management and shareholder interests. Detailed information on individual management quality or specific governance practices beyond regulatory filings usually requires deeper investigation of annual reports and public disclosures.
Outlook
Shree Ganesh Bio-Tech operates in a fundamentally essential and growing sector in India. The increasing demand for food and the ongoing shift towards hybrid seeds present a structural tailwind for the company. Its success hinges on its ability to continually innovate and develop high-performing, region-specific hybrid seeds that meet farmer needs, alongside maintaining an efficient distribution network. However, the company faces significant operational risks tied to weather patterns, crop cycles, and intense competition, which can lead to volatile financial performance. Its relatively smaller scale compared to industry leaders means it might have less R&D firepower and market influence. A balanced view suggests potential for growth driven by India's agricultural imperatives, but this is tempered by inherent industry cyclicality and competitive pressures that require strong execution and risk management.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 4 | 4 | 2 | 14 | 3 | 1 | 1 | 1 | 2 | 1 |
| Other Income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 5 | 4 | 2 | 15 | 3 | 2 | 1 | 1 | 2 | 2 |
| Total Expenditure | 4 | 4 | 2 | 14 | 4 | 1 | 1 | 1 | 3 | 2 |
| Operating Profit | 1 | 0 | 0 | 1 | -1 | 0 | 0 | 0 | -0 | -1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 0 | 0 | 1 | -1 | 0 | 0 | 0 | -0 | -1 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 1 | 0 | 0 | 1 | -1 | 0 | 0 | 0 | -0 | -1 |
| Adjustments | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 0 | 0 | 1 | -1 | 0 | 0 | 0 | -0 | -1 |
| Adjusted Earnings Per Share | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 2 | 2 | 9 | 8 | 6 | 2 | 17 | 73 | 62 | 20 | 23 | 5 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| Total Income | 2 | 2 | 9 | 8 | 6 | 2 | 17 | 73 | 63 | 21 | 24 | 6 |
| Total Expenditure | 1 | 1 | 5 | 4 | 4 | 2 | 17 | 69 | 60 | 20 | 24 | 7 |
| Operating Profit | 1 | 1 | 4 | 4 | 2 | 0 | 1 | 4 | 3 | 1 | 0 | -1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 1 | 4 | 4 | 2 | 0 | 0 | 3 | 3 | 1 | 0 | -1 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Profit After Tax | 0 | 1 | 4 | 4 | 2 | 0 | 0 | 3 | 2 | 1 | 0 | -1 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 1 | 4 | 4 | 2 | 0 | 0 | 3 | 2 | 1 | 0 | -1 |
| Adjusted Earnings Per Share | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0.1 | 0.1 | 0 | 0 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 15% | -32% | 63% | 28% |
| Operating Profit CAGR | -100% | -100% | 0% | -100% |
| PAT CAGR | -100% | -100% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -41% | -15% | -43% | NA% |
| ROE Average | 0% | 2% | 2% | 11% |
| ROCE Average | 1% | 2% | 3% | 8% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 4 | 5 | 19 | 23 | 57 | 57 | 58 | 60 | 62 | 63 | 63 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 1 | 1 | 0 | 3 | 7 | 7 | 17 | 33 | 17 | 11 | 0 |
| Total Liabilities | 5 | 5 | 19 | 26 | 64 | 65 | 75 | 94 | 80 | 74 | 63 |
| Fixed Assets | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 10 | 13 | 45 | 44 | 46 | 50 | 60 | 70 | 60 |
| Total Current Assets | 2 | 3 | 9 | 14 | 19 | 21 | 28 | 44 | 20 | 4 | 3 |
| Total Assets | 5 | 5 | 19 | 26 | 64 | 65 | 75 | 94 | 80 | 74 | 63 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -0 | -0 | -13 | 2 | -0 | -1 | 2 | 4 | 11 | 10 | -10 |
| Cash Flow from Investing Activities | -0 | 0 | 3 | -2 | -32 | 1 | -2 | -3 | -10 | -10 | 10 |
| Cash Flow from Financing Activities | 0 | -0 | 10 | 0 | 33 | 0 | 0 | -0 | 0 | 0 | 0 |
| Net Cash Inflow / Outflow | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0 | 1.02 | 0.96 | 0.04 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 | 0.01 |
| CEPS(Rs) | 0.12 | 0.17 | 1.02 | 0.96 | 0.04 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 | 0.01 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0 | 0 | 2.32 | 3.28 | 1.44 | 1.44 | 1.45 | 1.51 | 1.56 | 1.58 | 1.59 |
| Core EBITDA Margin(%) | 30.18 | 31.14 | 44.05 | 44.56 | 30.53 | 9.6 | 4.11 | 4.75 | 3.44 | -0.99 | -4.59 |
| EBIT Margin(%) | 24.51 | 29.37 | 44.05 | 44.55 | 30.51 | 9.56 | 2.49 | 4.82 | 4.35 | 4.22 | 1.69 |
| Pre Tax Margin(%) | 20.48 | 25.97 | 43.73 | 44.55 | 30.5 | 9.54 | 2.49 | 4.82 | 4.35 | 4.22 | 1.69 |
| PAT Margin (%) | 20.48 | 25.44 | 43.73 | 44.55 | 30.5 | 9.54 | 1.84 | 3.48 | 3.26 | 3.06 | 1.21 |
| Cash Profit Margin (%) | 26.15 | 28.92 | 43.73 | 44.55 | 30.52 | 9.58 | 1.84 | 3.48 | 3.27 | 3.06 | 1.21 |
| ROA(%) | 7.44 | 10.5 | 30.17 | 15.28 | 3.96 | 0.37 | 0.45 | 3 | 2.36 | 0.81 | 0.41 |
| ROE(%) | 8.48 | 11.97 | 56.2 | 34.12 | 5.17 | 0.41 | 0.55 | 4.28 | 3.32 | 0.99 | 0.44 |
| ROCE(%) | 9.1 | 12.3 | 30.44 | 16.48 | 4.45 | 0.41 | 0.74 | 5.92 | 4.43 | 1.36 | 0.61 |
| Receivable days | 192.07 | 331.63 | 248.8 | 522.81 | 1016.27 | 2948.42 | 520.89 | 181.46 | 184.73 | 203.69 | 0 |
| Inventory Days | 214.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 45.95 |
| Payable days | 38.21 | 0 | 0.99 | 179.68 | 541.32 | 1588.45 | 263.54 | 129.48 | 149.35 | 244.63 | 0 |
| PER(x) | 0 | 0 | 0 | 20.71 | 133.62 | 1100.59 | 750 | 73.34 | 19.96 | 67.31 | 128.57 |
| Price/Book(x) | 0 | 0 | 0 | 6.04 | 4.18 | 4.52 | 4.09 | 3.07 | 0.65 | 0.66 | 0.57 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 1.35 | 1.09 | 0.22 | 9.25 | 40.78 | 105 | 13.73 | 2.55 | 0.64 | 2.04 | 1.56 |
| EV/Core EBITDA(x) | 4.48 | 3.33 | 0.5 | 20.75 | 133.57 | 1093.61 | 333.77 | 52.95 | 14.8 | 48.42 | 92.57 |
| Net Sales Growth(%) | -25.58 | 25.82 | 302.84 | -7.95 | -25.31 | -57.86 | 596.07 | 322.01 | -14.03 | -67.53 | 13.22 |
| EBIT Growth(%) | 95.45 | 50.79 | 504.16 | -6.91 | -48.84 | -86.8 | 81.26 | 716.77 | -22.44 | -68.5 | -54.75 |
| PAT Growth(%) | 107.13 | 56.35 | 592.39 | -6.24 | -48.87 | -86.82 | 34.31 | 697.39 | -19.29 | -69.55 | -55.15 |
| EPS Growth(%) | 0 | 0 | 592.37 | -6.23 | -95.3 | -86.83 | 33.56 | 702.53 | -19.4 | -69.47 | -55.13 |
| Debt/Equity(x) | 0.14 | 0.1 | 0.01 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 3.2 | 5.19 | 690.15 | 4.11 | 2.89 | 2.96 | 1.71 | 1.32 | 1.16 | 0.35 | 14.65 |
| Quick Ratio(x) | 1.9 | 5.19 | 690.15 | 4.11 | 2.89 | 2.96 | 1.71 | 1.32 | 1.16 | 0.35 | 2.18 |
| Interest Cover(x) | 6.08 | 8.64 | 138.11 | 0 | 2251.62 | 444.33 | 1072.24 | 0 | 0 | 8550 | 0 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +15% | -32% | +63% | +28% |
| Operating Profit CAGR | -100% | -100% | — | -100% |
| PAT CAGR | -100% | -100% | — | — |
| Share Price CAGR | -41% | -15% | -43% | — |
| ROE Average | 0% | +2% | +2% | +11% |
| ROCE Average | +1% | +2% | +3% | +8% |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 | 1.42 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 | 0.57 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 | 39.3 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 | 39.86 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.